House Bill 4106
116th Congress(2019-2020)
Responsibility in Drug Advertising Act of 2019
Introduced
Introduced in House on Jul 30, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
4106
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Responsibility in Drug Advertising Act of 2019
This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.July 30, 2019
Sort by most recent
07/31/2019
Referred to the Subcommittee on Health.
07/30/2019
Referred to the House Committee on Energy and Commerce.
07/30/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:50:16 PM